INDIANAPOLIS — A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.
The drug makers presented data from three pooled analyses of Tradjenta (linagliptin) at the 48th annual meeting of the European Association for the Study of Diabetes. The studies found Tradjenta effective when used alone or combined with other therapies in lowering hemoglobin A1C. Data from a fourth study found that compared with placebo, adding the drug to a stable dose of basal insulin improved blood-glucose control over 52 weeks without an additional risk of abnormally low blood sugar, known as hypoglycemia, or weight gain.
"We are committed to developing and providing therapeutic solutions, such as linagliptin, for adult patients with Type 2 diabetes," Boehringer Ingelheim VP metabolic-clinical development and medical affairs Christophe Arbet-Engels said. "We look forward to continuing our ongoing clinical trial program to assess how linagliptin may address the various needs of these patients."